Skip to content
Triangle logo TriangleGet started
← All settings

DISEASE & TREATMENT SETTING

KIMMTRAK: unresectable metastatic Uveal melanoma

Source-derived catalogue. This is not a treatment recommendation or a personalised trial match.

Exact scope

KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma ( 1 , 2.1 ).

Broader topic: Intraocular (Uveal) Melanoma

Source population
Not part of this definition
Disease extent
metastatic
Treatment line
Not part of this definition
Stage
Not part of this definition
Resectability
unresectable
Biomarkers, prior therapy and derivation
molecular
    prior therapy
      derivation status
      source-attested
      derivation note
      Scoped from the FDA approved indication for KIMMTRAK (product label). Only dimensions stated in that wording are part of this definition.
      source wording
      KIMMTRAK is a bispecific gp100 peptide-HLA-directed CD3 T cell engager indicated for the treatment of HLA-A*02:01-positive adult patients with unresectable or metastatic uveal melanoma ( 1 , 2.1 ).

      Study evidence for this setting

      1 linked studies · Applicability is a draft source assessment, not a determination of your eligibility.

      NCT00445965 · Registry condition search · Scope: unclear

      Iodine I 131 Monoclonal Antibody 3F8 in Treating Patients With Central Nervous System Cancer or Leptomeningeal Cancer

      3 outcome links · 1 safety-group records · 0 quality-of-life measures

      →
      Source relationships and population-mapping limitations
      bindings
        mappings

          Download this complete draft source relationship record →

          Preserved source evidence · Not medical advice